TY - JOUR
T1 - Ad26.COV2.S priming provided a solid immunological base for mRNA-based COVID-19 booster vaccination
AU - Geers, Daryl
AU - Sablerolles, Roos S.G.
AU - SWITCH Research Group
AU - van Baarle, Debbie
AU - Kootstra, Neeltje A.
AU - Rietdijk, Wim J.R.
AU - Schmitz, Katharina S.
AU - Gommers, Lennert
AU - Bogers, Susanne
AU - Nieuwkoop, Nella J.
AU - van Dijk, Laura L.A.
AU - van Haren, Eva
AU - Lafeber, Melvin
AU - Dalm, Virgil A.S.H.
AU - Goorhuis, Abraham
AU - Postma, Douwe F.
AU - Visser, Leo G.
AU - Huckriede, Anke L.W.
AU - Sette, Alessandro
AU - Grifoni, Alba
AU - de Swart, Rik L.
AU - Koopmans, Marion P.G.
AU - van der Kuy, P. Hugo M.
AU - GeurtsvanKessel, Corine H.
AU - de Vries, Rory D.
N1 - Publisher Copyright:
© 2022 The Author(s)
PY - 2023/1/20
Y1 - 2023/1/20
N2 - The emergence of novel SARS-CoV-2 variants led to the recommendation of booster vaccinations after Ad26.COV2.S priming. It was previously shown that heterologous booster vaccination induces high antibody levels, but how heterologous boosters affect other functional aspects of the immune response remained unknown. Here, we performed immunological profiling of Ad26.COV2.S-primed individuals before and after homologous or heterologous (mRNA-1273 or BNT162b2) booster. Booster vaccinations increased functional antibodies targeting ancestral SARS-CoV-2 and emerging variants. Especially heterologous booster vaccinations induced high levels of functional antibodies. In contrast, T-cell responses were similar in magnitude following homologous or heterologous booster vaccination and retained cross-reactivity towards variants. Booster vaccination led to a minimal expansion of SARS-CoV-2-specific T-cell clones and no increase in the breadth of the T-cell repertoire. In conclusion, we show that Ad26.COV2.S priming vaccination provided a solid immunological base for heterologous boosting, increasing humoral and cellular responses targeting emerging variants of concern.
AB - The emergence of novel SARS-CoV-2 variants led to the recommendation of booster vaccinations after Ad26.COV2.S priming. It was previously shown that heterologous booster vaccination induces high antibody levels, but how heterologous boosters affect other functional aspects of the immune response remained unknown. Here, we performed immunological profiling of Ad26.COV2.S-primed individuals before and after homologous or heterologous (mRNA-1273 or BNT162b2) booster. Booster vaccinations increased functional antibodies targeting ancestral SARS-CoV-2 and emerging variants. Especially heterologous booster vaccinations induced high levels of functional antibodies. In contrast, T-cell responses were similar in magnitude following homologous or heterologous booster vaccination and retained cross-reactivity towards variants. Booster vaccination led to a minimal expansion of SARS-CoV-2-specific T-cell clones and no increase in the breadth of the T-cell repertoire. In conclusion, we show that Ad26.COV2.S priming vaccination provided a solid immunological base for heterologous boosting, increasing humoral and cellular responses targeting emerging variants of concern.
UR - http://www.scopus.com/inward/record.url?scp=85144411101&partnerID=8YFLogxK
U2 - 10.1016/j.isci.2022.105753
DO - 10.1016/j.isci.2022.105753
M3 - Article
AN - SCOPUS:85144411101
SN - 2589-0042
VL - 26
JO - iScience
JF - iScience
IS - 1
M1 - 105753
ER -
